Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/64718
Título
Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders
Autor
Año del Documento
2022
Documento Fuente
Neurology Neuroimmunollogy & Neuroinflammation 2021 Jan 10;9(1):e1101
Abstract
Background and Objectives To investigate whether children receiving immunosuppressive therapies for neuroimmunologic disorders had (1) increased susceptibility to SARS-CoV2 infection or to develop more severe forms of COVID-19; (2) increased relapses or autoimmune complications if infected; and (3)
changes in health care delivery during the pandemic.
Methods Patients with and without immunosuppressive treatment were recruited to participate in a
retrospective survey evaluating the period from March 14, 2020, to March 30, 2021. Demographics, clinical features, type of immunosuppressive treatment, suspected or confirmed COVID-19 in the patients or cohabitants, and changes in care delivery were recorded.
Results One hundred fifty-three children were included: 84 (55%) female, median age 13 years
(interquartile range [8–16] years), 79 (52%) on immunosuppressive treatment. COVID-19
was suspected or confirmed in 17 (11%) (all mild), with a frequency similar in patients with and
without immunosuppressive treatment (11/79 [14%] vs 6/74 [8%], p = 0.3085). The frequency of neurologic relapses was similar in patients with (18%) and without (21%) COVID19. Factors associated with COVID-19 included having cohabitants with COVID-19 (p <0.001) and lower blood levels of vitamin D (p = 0.039). Return to face-to-face schooling or mask type did not influence the risk of infection, although 43(28%) children had contact with a classmate with COVID-19. Clinic visits changed from face to face to remote for 120 (79%) patients; 110 (92%) were satisfied with the change.
Discussion In this cohort of children with neuroimmunologic disorders, the frequency of COVID-19 was
low and not affected by immunosuppressive therapies. The main risk factors for developing COVID-19 were having cohabitants with COVID-19 and low vitamin D levels
Revisión por pares
SI
Idioma
spa
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Collections
Files in this item
![Attribution-NonCommercial-NoDerivatives 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-by-nc-nd.png)